Compare Icl Group Ltd (ICL) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Health Care Select Sector SPDR Fund — how do they compare? Icl Group Ltd trades at $5.03 (market cap $6.47B), while Health Care Select Sector SPDR Fund trades at $170.67 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 6.7× Icl Group Ltd's market cap, and Icl Group Ltd pays a 4.11% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| ICL | XLV | |
|---|---|---|
Market Cap | $6.47B | $43.48B |
Volume | 1,387,140 | 11,121,431 |
Sector | Basic Materials | — |
52-Week High | $6.84 | $175.68 |
52-Week Low | $4.80 | $141.95 |
Typical Hold Time | 56 Days | 100 Days |
Enterprise Value | $9.11B | — |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no recent price movement. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported $7.15B revenue in 2025 with a 3.95% net margin, while valuation ratios appear reasonable with P/E of 20.83 and P/S of 0.84. Recent earnings showed Q2 2026 beat expectations with $0.12 EPS versus $0.11 expected. The company maintains stable cash flow generation despite recent net cash outflows.
ICL presents a cautious opportunity with 19.7% upside to the $6.08 consensus price target, though analyst sentiment is neutral with 100% hold ratings. Key risks include fertilizer industry headwinds from higher input costs and competitive pressures. The dividend yield of approximately 1.2% provides income support while investors await earnings recovery toward projected 2026 profitability improvement.
XLV trades at $169.58 with a slight 0.46% daily gain amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent news highlights XLV's competitive expense ratio of 0.08% and defensive healthcare sector positioning. Options activity shows increased put volume, suggesting some investor caution despite the fund's diversification across 61 healthcare stocks.
The healthcare ETF presents a cost-effective defensive play with potential upside if political volatility subsides post-elections. Key risks include sector-specific regulatory pressures and biotech trial failures impacting holdings. Current technical weakness near support at $166 requires monitoring for potential breakdown, though the fund's low fees and broad diversification provide stability during market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
